Hong Kong Pharma Digital Technology Holdings Limited is a pioneering entity in the biotechnology and digital healthcare sectors, focused on enhancing patient outcomes through innovative pharmaceutical services. By harnessing cutting-edge digital technologies and sophisticated data analytics, the company optimizes drug development and boosts operational efficiencies, positioning itself as a key player in the dynamic healthcare landscape. With a commitment to health technology advancement and strategic collaborations, Hong Kong Pharma is well-equipped to meet the evolving needs of both domestic and international markets while propelling innovation within its extensive service offerings.
| Revenue (TTM) | $16.36M |
| Gross Profit (TTM) | $1.44M |
| EBITDA | -534,478 |
| Operating Margin | 2.96% |
| Return on Equity | -13.40% |
| Return on Assets | -3.94% |
| Revenue/Share (TTM) | $1.53 |
| Book Value | $0.47 |
| Price-to-Book | 2.03 |
| Price-to-Sales (TTM) | 0.61 |
| EV/Revenue | 0.627 |
| EV/EBITDA | 23.77 |
| Quarterly Earnings Growth (YoY) | -83.10% |
| Quarterly Revenue Growth (YoY) | -35.70% |
| Shares Outstanding | $16.35M |
| Float | $7.36M |
| % Insiders | 33.13% |
| % Institutions | 0.32% |
Volatility is currently contracting